Shanghai Healthcare Capital

Brattea is a medical device research and development company specializing in renal denervation products aimed at addressing various health conditions, including hypertension, cancer pain, and diabetes. The company develops interventional devices that include renal artery ablation catheters, radiofrequency ablation equipment, and medical mapping systems. These products are designed to treat a range of medical issues, such as refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Through its innovative approach, Brattea aims to provide reliable solutions that improve patient outcomes and enhance the quality of care in the medical field.

Geneos Therapeutics, Inc. is a biotechnology company that specializes in the development of neoantigen-targeting cancer immunotherapies. Founded in 2016 and located in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies based on the unique tumor mutations of individual patients. By identifying relevant neoantigen targets from each patient's tumor, Geneos aims to develop innovative treatments that provide targeted immunotherapy options for various types of cancer. This approach is designed to empower oncologists with tailored solutions to improve patient outcomes in cancer treatment.

Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.

ReLive Biotechnologies is a biotechnology company focused on developing innovative solutions in orthopedic sports medicine and plastic and reconstructive surgery. The company specializes in cartilage regeneration and repair technologies aimed at treating various cartilage defects, including articular hyaline cartilage, osteochondral, and meniscal injuries. ReLive employs a unique approach that combines multi-source cells with 3D printing bioscaffold materials, facilitating the creation of advanced medical products. These innovations not only enhance treatments for orthopedic conditions but also provide essential supplies for plastic surgeons, underscoring the company's commitment to advancing regenerative medicine and cell therapy.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company aims to address unmet medical needs by identifying, developing, and commercializing differentiated medicines. ArriVent is advancing its lead development candidate, furmonertinib, alongside a pipeline of novel therapeutics, including next-generation antibody drug conjugates. The company's efforts are primarily centered on solid tumors, leveraging the team's extensive experience in drug development to enhance the potential of its therapeutic candidates from initial development through to approval and commercialization.

Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI-related disorders.

Ranok Therapeutics is a biotechnology company specializing in the development of innovative targeted protein degradation technology to facilitate the discovery and development of new therapeutics. This technology engages various biological processes and aims to surpass existing methods in the field. Ranok's research pipeline includes both established and novel drug targets that address cancer and other diseases with considerable unmet medical needs. The company is committed to creating the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery, development, and manufacturing of innovative immuno-oncology therapies. Founded in 2016 by a team of experienced professionals from leading pharmaceutical companies, Abbisko is dedicated to developing small molecule inhibitors, including ABSK011 and ABSK021, for the treatment of hepatocellular carcinoma, as well as CSF1R for solid tumors. In addition to oncology, the company is engaged in developing therapeutics for various conditions, including cancer, liver diseases, diabetes, metabolic disorders, viral infections, and central nervous system diseases.

Immvira, established in Shenzhen, China, in May 2015, is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Founded by a team of renowned researchers, including Professors from prestigious institutions, Immvira specializes in biopharmaceutical technology centered on oncolytic viruses and vector-based methods. The company’s flagship product is a genetically engineered Oncolytic Herpes Simplex Virus, designed to target metastatic tumors and those that are difficult to reach through traditional injection methods. By leveraging its advanced biotechnology platform, Immvira aims to improve treatment outcomes for cancer patients, providing effective therapeutic options for challenging tumor types.

VeriSilicon, headquartered in Santa Clara, California, with an additional office in Plano, Texas, is a semiconductor company specializing in custom silicon solutions and system-on-chip (SoC) turnkey services. It offers a wide range of services, including the design and manufacture of memory chips, and provides licensable digital signal processing cores, Hantro Video IPs, and eDRAM. VeriSilicon caters to diverse industries such as smartphones, media tablets, HDTVs, set-top boxes, and data centers, targeting advanced process technologies like 28nm and FD-SOI. The company's portfolio includes five types of in-house processor IPs and over 1,400 analog and mixed signal IPs and RF IPs, enabling it to deliver comprehensive, customized silicon solutions.